A Closer Look At China’s 2012 Essential Drug Expansion
This article was originally published in The Pink Sheet Daily
Executive Summary
China is likely to focus on drugs with large consumption patterns for the revised EDL, including anti-hypertensive drugs and oncology drugs.
You may also be interested in...
Hospira Hinges Emerging Market Success On Scale And Differentiation
Hospira Inc.'s new CEO Michael Ball laid out the company's strategic moves to expand in the fast-growing emerging markets during the company's Sept. 7 Investor's Day conference. The CEO said the U.S.-centric company's future growth hinges on expanding its footprint in emerging markets and launching more products including biosimilars in top pharmaceutical markets in Europe and Japan
In China, A Province's Drastic Price Cut Model Is Being Modified To Fit A Nationwide System: A Look At The Anhui Model
SHANGHAI - Since China's healthcare reforms started in 2009, the central government has been encouraging local government to pilot different tender models for essential drugs to reduce public medical expenses. Anhui Province's tender system became a successful example by reducing essential drug prices an average 40-50% last year, and now the central government is implementing a single supplier procurement system, the so-called Anhui model, nationwide
Merck Expands Manufacturing Site In China As Part Of Its Global Restructuring Program
SHANGHAI - Merck announced it would invest $162 million to expand its capacity in China by building a new manufacturing facility, shortly after the company detailed its plans to integrate its R&D, manufacturing and business operations worldwide